1-4 of 4 Activities
In this CME Outfitters livestream symposium, expert faculty will discuss recognizing the frequency of bowel urgency in patients with CD and the impact to patient QoL, incorporating assessments for bowel urgency as part of thorough symptom evaluation for patients with CD, and engaging patients in open communication about their bowel urgency as part of shared decision-making in order to improve clinical outcomes.
Millie D. Long, MD, MPH, is board certified in internal medicine, preventive medicine, and gastroenterology. Dr. Long received her medical degree from University of Virginia in 2002. She then completed residency in internal medicine and a chief residency at University of Alabama at Birmingham. She completed fellowships in gastroenterology and hepatology, preventive medicine, and inflammatory bowel disease, all at University of North Carolina. She is currently Professor of Medicine in the Department of Medicine and Director of the Gastroenterology and Hepatology Fellowship Program at University of North Carolina at Chapel Hill.
Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) Center. Her research interests include prevention of complications of IBD, women’s health, and clinical epidemiology. Dr. Long has contributed to over 200 peer-reviewed publications, book chapters, and review articles and to the medical literature. She is the current co-Editor in Chief of the American Journal of Gastroenterology. She also serves as an invited reviewer for journals such as Inflammatory Bowel Diseases and Gastroenterology.
Dr. Long is a fellow of the American College of Gastroenterology, where she serves on the Board of Trustees. She is also a fellow of the American Gastroenterological Association and the Crohn’s and Colitis Foundation, where she co-chairs the Clinical Research Alliance.
Anemia occurs frequently in patients with inflammatory bowel disease (IBD) and is one of the most commonly seen extraintestinal manifestations of disease with iron deficiency (ID) as the most common cause. Practice guidelines recommend screening all patients with IBD regularly for ID and anemia, but studies show screening is done infrequently. Additionally, patients with IBD and iron deficiency anemia (IDA) require specific considerations for the presence of active inflammation when determining whether IV or oral iron supplementation is appropriate as elevated hepcidin levels in active IBD can block oral iron absorption.
This CME Outfitters symposium entitled, Forging a New Frontier: Revolutionizing Iron Deficiency Therapy in Patients with Inflammatory Bowel Disease, will feature globally renowned faculty who will discuss screening for ID in patients with IBD, the role of hepcidin in ID pathophysiology, and the basic principles of iron metabolism and absorption, including the distinction between absolute and functional ID. The expert panel will also explore the differences between oral and intravenous (IV) iron formulations; evaluate clinical trial efficacy data on IV iron in both adult and pediatric patients; and review shared decision-making strategies.
Gary R. Lichtenstein, MD, is the Vice Chief, Division of Gastroenterology, Development and Philanthropy; Emeritus Director of the Inflammatory Bowel Disease Program; and Professor of Medicine in the Gastrointestinal Division of the Department of Medicine at the Hospital of the University of Pennsylvania and the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania. Dr. Lichtenstein earned his medical degree from the Mount Sinai School of Medicine in New York, New York. He then completed his internship and residency in internal medicine at Duke University Medical Center in Durham, North Carolina. He also served a fellowship in gastroenterology at the Hospital of the University of Pennsylvania of the University of Pennsylvania School of Medicine. His current research interests encompass investigational therapies for the treatment of ulcerative colitis and Crohn’s disease and his research has had a significant focus on the safety of current and future medical therapy. He has also focused his research on the natural history of disease. Dr. Lichtenstein has received numerous research grants focusing on these areas and has served as the national/international principal investigator evaluating novel agents for therapeutic trials in the treatment of ulcerative colitis and Crohn’s disease.
A Fellow of the American Gastroenterological Association (AGA), the American College of Physicians, and the American College of Gastroenterology, Dr. Lichtenstein is listed in Best Doctors in America (inflammatory bowel disease [IBD]) and has served as Medical Secretary for the American Board of Internal Medicine, Gastroenterology Section. He holds membership and committee positions in many professional societies at a national level, including the AGA where he has served as Vice Chair of the Clinical Practice Committee and Practice Economics Committee and where he has served as Chair of the Clinical Practice Committee; the American Society for Gastrointestinal Endoscopy where he has served on the committee on training; and the American College of Gastroenterology where he has served on the Education Committee, Programs Committee, and Nominations Committee. He recently served as a member of the research committee. He has been the chair of numerous abstract review committees for IBD for the American College of Gastroenterology and the AGA and has served as section chair and moderator for numerous sessions at Digestive Disease Week. Dr. Lichtenstein is also a member of the Crohn’s and Colitis Foundation of America where he served at the national level as the chair of the membership committee of the Clinical Research Alliance, on the National Grants Review Committee, on the National Physician Education Committee, and currently as chair of the Membership Committee. Additionally, he is a longstanding member of the American College of Physicians and the American Medical Association.
Dr. Lichtenstein has received numerous awards, including the National Scientific Achievement Award from the national Crohn’s and Colitis Foundation of America (CCFA), for his clinical work and research. In 2020, he was recipient of the AGA’s top academic clinician award (the AGA Distinguished Clinician Award in Academic Practice). He received the award for the top specialist in the University of Pennsylvania Health System (the Louis A. Duhring Award) as well as the top teaching award in all of University of Pennsylvania (the Christian R. and Mary F. Lindback Award). Additionally, he has received the medical school teaching award (the Penn Pearls Award), the Department of Medicine house staff teaching award (the Donald B. Martin Teaching Award), and the Gastroenterology Division teaching award (the Sidney Cohen Teaching Award).
Dr. Lichtenstein is listed in Philadelphia Magazine among top gastroenterologists for elderly in Philadelphia and among top gastroenterologists in Philadelphia (special focus: IBD). He is the recipient of the CCFA Physician of the Year Award: Philadelphia and Delaware Valley Chapters.
In addition to having served on the editorial board of the journals Gastroenterology, American Journal of Gastroenterology, Inflammatory Bowel Diseases, World Journal of Gastroenterology, and Digestive Diseases and Sciences, Dr. Lichtenstein served as a former writer of Selected Summaries in the journal Gastroenterology and as the Section Editor of Selected Summaries as well as Print and Media Review in Gastroenterology for a 5-year term. He has been and is currently serving as a reviewer for journals such as The New England Journal of Medicine,Gastroenterology, The Lancet, Annals of Internal Medicine, Clinical Gastroenterology and Hepatology, Gut, Journal of Parenteral and Enteral Nutrition, The American Journal of Gastroenterology, World Journal of Gastroenterology, and Journal of Clinical Gastroenterology. He is the journal founder and Executive Editor of the PubMed-indexed journal Gastroenterology and Hepatology, now in press for 18 years, and has served as Associate Editor of Therapeutic Advances in Gastroenterology, The Physician and Sports Medicine, and Clinical Investigation and has served as Assistant Editor-in-Chief of World Journal of Gastroenterology. He is the author or coauthor of more than 150 primary research articles, 280 chapters, editorials, and reviews, has edited 32 books, and has presented over 350 abstracts. Dr. Lichtenstein has been an invited speaker at the local, national, and international levels, speaking at over 500 conferences, lectures, symposia, and institutional grand rounds.
Neilanjan Nandi, FACG, AGAF, FACP, is Associate Professor of Clinical Medicine at Penn Presbyterian Medical Center at the University of Pennsylvania. Dr. Nandi’s practice focuses on the management of inflammatory bowel disease (IBD) (e.g., Crohn’s disease, ulcerative colitis) and recurrent Clostridium difficile (C. difficile) infection via fecal microbiota transplantation (FMT). Dr. Nandi serves on the executive council of the Philadelphia Crohn’s & Colitis Foundation (CCF) and on the medical advisory board of the United Ostomy Associates of America (UOAA), coordinates outreach on the American College of Gastroenterology Patient Care Committee, and is a founding board member of the South Asian IBD Alliance (SAIA). He also regularly peer reviews research publications and serves on the social media editorial board for the premier journals Inflammatory Bowel Diseases and Crohn’s & Colitis 360. His research has focused on studying conditions co-morbid to IBD quality of care, namely the diagnosis and management of refractory C. difficile infection and the application of FMT in C. difficile; also, characterizing the management and consequences of iron deficiency anemia and non-alcoholic fatty liver disease in patients with IBD. Dr. Nandi has authored numerous book chapters on the diagnosis and management of various viral, parasitic, mycobacterial, and bacterial infections of the gastrointestinal (GI) tract.
Dr. Nandi’s fervor for clinical education has been recognized with multiple teaching awards. He was honored as the 2019 Physician Hero by the Philadelphia/Delaware Valley Crohn’s and Colitis Foundation at their annual Take Steps for Crohn’s & Colitis event, and wields digital and social media platforms to amplify education, outreach, and advocacy in IBD to clinicians and patients. He was also awarded the Philadelphia CCF’s Chairman’s Citation in 2022. He is the regular host of the academic podcast GI Insights: IBD Crosstalk, which features high-yield, evidence-based medicine discussions with guests from different interdisciplinary fields critical to providing comprehensive IBD care. Dr. Nandi’s passions include fitness, cooking, virtual reality gaming, reading, and dancing. Follow him on social @fitwitmd.
In this CME Outfitters livestream symposium, expert faculty will review the role of the IL-23/Th-17 pathway in the pathogenesis of IBD and utilize animated 3-D models to illustrate differences in agents in the anti-IL-23 class that may have potential therapeutic implications. Learners will be guided through an evaluation of the potential clinical implications of CD64 receptor binding by anti-IL-23 mAbs in IBD treatment, as well as the clinical evidence supporting the benefits of these IBD treatment features.
Miguel Regueiro earned his bachelor’s degree at the University of Pennsylvania, his medical degree at Drexel (Hahnemann) University and completed his internal medicine internship, residency, and clinical and research fellowship training in gastroenterology at Harvard Medical School’s Beth Israel Hospital.
Dr. Regueiro was Professor of Medicine and Clinical and Translational Science at the University of Pittsburgh School of Medicine from 2000 to 2018. There he served as the IBD Clinical Medical Director, Senior Medical Lead of Specialty Medical Homes, was Professor with Tenure, and honored as the UPMC Endowed Chair for Patient Centered Care in Inflammatory Bowel Diseases.
Dr. Regueiro is currently the Chair of the Department of Gastroenterology and Hepatology and Chair of the Digestive Disease and Surgery Institute at Cleveland Clinic in Ohio. He serves as Medical Co- Chair of Digestive Disease and Surgical Institute Research Governance committee and is Professor of Medicine at the Lerner College of Medicine, Cleveland Clinic.
Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases with a focus on the natural course of these diseases and postoperative prevention of Crohn’s disease. Recently, he has been involved in transformative medicine initiatives and developing new models of healthcare, including the first-of-its kind specialty medical home for IBD. Dr. Regueiro is investigating alternative models of care in population-based health that integrates patients, payers, providers, pharmaceutical industry, and other facets of healthcare delivery around these novel programs.
In this CME Outfitters live webcast, leading clinical experts will help prepare learners to discuss, assess, and address bowel urgency in patients with CD, and will provide insight into the efficacy and safety of new and emerging therapies. The webcast will also include videos capturing the patient journey and first-hand experiences.
